New hope for lung cancer patients: drug combo targets tough tumors

This study tests a new combination of two drugs (becotatug vedotin and pucotenlimab), with or without radiation, as a first treatment for people with advanced non-small cell lung cancer that has a specific protein (EGFR) on its surface. About 39 participants will receive the drugs every 3 weeks for 4 cycles, then continue one drug alone to keep the cancer under control. The goal is to see if this approach shrinks tumors and slows disease progression.